Urgent PC

New Products: BPH surgical robot granted FDA de novo requestOther products highlighted in this round-up include a plate for studying infections caused by the long-term use of catheters and a new indication for sunitinib malate (SUTENT).
PTNS efficacy bolstered by adjunctive pharmacotherapyStudy examines real-world effectiveness of percutaneous tibial nerve stimulation for treating overactive bladder.
Coverage for OAB nerve stim device expands
Coverage for OAB nerve stim device expandsUroplasty, Inc. announced that Cigna has written a positive coverage policy for percutaneous tibial nerve stimulation delivered via Uroplasty's Urgent PC neuromodulation system for treatment of overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence.
PTNS for overactive bladder: Patient selection and technique
PTNS for overactive bladder: Patient selection and techniqueThis article provides a real-world definition of refractory overactive bladder and its prevalence, then examines treatment options, with a focus on percutaneous tibial nerve stimulation as a noninvasive form of neuromodulation “for the masses.”
Coverage expands for prostate cancer test, PTNSInsurance coverage has expanded for an epigenetic test for prostate cancer and percutaneous tibial nerve stimulation (PTNS) for the treatment of overactive bladder (OAB).
Humana issues positive coverage policy for percutaneous tibial nerve stimulationUroplasty announced that Humana, Inc. has written a positive coverage policy for percutaneous tibial nerve stimulation delivered via its Urgent PC Neuromodulation System.
PTNS therapy for OAB found durable at 3 yearsThe effect of percutaneous tibial nerve stimulation in patients with overactive bladder appears to be durable at up to 3 years, a recently published study demonstrates.